124
Participants
Start Date
January 11, 2023
Primary Completion Date
November 14, 2024
Study Completion Date
November 14, 2024
dupilumab
Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
Topical emollient (moisturizer)
Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
Markowitz Medical, New York
Philip Fried, MD PLLC, The Bronx
SUNY Downstate Medical Center, Brooklyn
NYC Health + Hospital , Elmhurst Hospital Center, Elmhurst
Callender Dermatology and Cosmetic Center, Glenn Dale
Dermatology and Skin Cancer Specialists, LLC dba US Dermatology Partners, Rockville
Duke University Medical Center, Durham
National Allergy and Asthma Research, LLC., North Charleston
Advanced Medical Research PC, Atlanta
Atlanta Biomedical Clinical Research LLC, Atlanta
University of Miami Miller School of Medicine, Miami
Skin and Cancer Associates, LLP, Miami
Century Research LLC, Miami
Total Skin & Beauty Dermatology Center, Birmingham
The University Of Alabama At Birmingham, Birmingham
C2 Research Center, LLC, Montgomery
Revival Research Institute , LLC, Troy
Wayne State University Physician Group Dermatology, Dearborn
Northwestern Memorial Hospital, Chicago
Washington University School of Medicine, St Louis
Center for Clinical Studies, LTD.LLP, Houston
Heights Dermatology & Aesthetic Center - Heights Location, Houston
RFSA Dermatology, San Antonio
Texas Dermatology and Laser Specialists, San Antonio
UCSD/ Rady Children's Hospital, San Diego
UCSF, San Francisco
SF Research Institute, San Francisco
Center for Dermatology Clinical Research, inc., Fremont
Oregon Health & Science University, Portland
Rao Dermatology, Atlantic Highlands
Collaborators (1)
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY